(Q36494210)

14 August 2017

1 reference

title

Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases (English)

1 reference

14 August 2017

0 references

0 references

Burkhard Möller

1

0 references

Peter Villiger

series ordinal

2

object named as

Peter M Villiger

1 reference

14 August 2017

publication date

9 May 2006

1 reference

Seminars in Immunopathology

14 August 2017

published in

1 reference

14 August 2017

volume

27

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

391-408

1 reference

Directing transition from innate to acquired immunity: defining a role for IL-6.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00281-006-0012-9

A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-006-0012-9

TNF Deficiency Fails to Protect BAFF Transgenic Mice against Autoimmunity and Reveals a Predisposition to B Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-006-0012-9

Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-006-0012-9

The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-006-0012-9

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-006-0012-9

Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-006-0012-9

T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles

21 January 2018

1 reference

12 December 2020

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

1 reference

12 December 2020

1 reference

12 December 2020

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells.

1 reference

12 December 2020

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

12 December 2020

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

12 December 2020

Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial

1 reference

12 December 2020

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

1 reference

12 December 2020

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

1 reference

12 December 2020

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

1 reference

12 December 2020

The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice

1 reference

12 December 2020

Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

1 reference

12 December 2020

Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice

1 reference

12 December 2020

The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families

1 reference

12 December 2020

Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling

1 reference

12 December 2020

Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group

1 reference

12 December 2020

DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition

1 reference

12 December 2020

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

1 reference

12 December 2020

Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis

1 reference

12 December 2020

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

1 reference

12 December 2020

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

12 December 2020

Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements

1 reference

12 December 2020

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

12 December 2020

Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis.

1 reference

12 December 2020

Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis

1 reference

12 December 2020

Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation

1 reference

12 December 2020

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

1 reference

12 December 2020

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

1 reference

12 December 2020

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

12 December 2020

Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation

1 reference

12 December 2020

Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.

1 reference

12 December 2020

Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins

1 reference

12 December 2020

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

1 reference

12 December 2020

Interleukin 6 plays a key role in the development of antigen-induced arthritis

1 reference

12 December 2020

Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist

1 reference

12 December 2020

Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children

1 reference

12 December 2020

Interleukin 6 is required for the development of collagen-induced arthritis

1 reference

12 December 2020

The TNF-alpha transgenic mouse model of inflammatory arthritis

1 reference

12 December 2020

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

12 December 2020

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

1 reference

12 December 2020

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

12 December 2020

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

12 December 2020

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

12 December 2020

Biologic basis for interleukin-1 in disease

1 reference

12 December 2020

Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice

1 reference

12 December 2020

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

12 December 2020

IgG1 plasmacytosis in interleukin 6 transgenic mice

1 reference

12 December 2020

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

12 December 2020

IL-6 in autoimmune disease and chronic inflammatory proliferative disease

1 reference

12 December 2020

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

12 December 2020

Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice

1 reference

12 December 2020

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

12 December 2020

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

12 December 2020

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

1 reference

12 December 2020

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

12 December 2020

The balance between IL-1 and IL-1Ra in disease

1 reference

12 December 2020

IL-1ra administration does not improve cardiac function in patients with severe sepsis

1 reference

12 December 2020

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

12 December 2020

Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders.

1 reference

12 December 2020

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

1 reference

12 December 2020

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

12 December 2020

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

12 December 2020

Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias

1 reference

12 December 2020

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

12 December 2020

Etanercept and uveitis in patients with juvenile idiopathic arthritis.

1 reference

12 December 2020

Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study

1 reference

12 December 2020

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

1 reference

12 December 2020

Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling

1 reference

12 December 2020

Castleman's disease in POEMS syndrome with elevated interleukin-6

1 reference

12 December 2020

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

1 reference

12 December 2020

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

1 reference

12 December 2020

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

12 December 2020

CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation

1 reference

12 December 2020

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

1 reference

12 December 2020

A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling

1 reference

12 December 2020

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

1 reference

12 December 2020

Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome

1 reference

12 December 2020

IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells.

1 reference

12 December 2020

Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study

1 reference

12 December 2020

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

1 reference

12 December 2020

The point mutation of tyrosine 759 of the IL-6 family cytokine receptor gp130 synergizes with HTLV-1 pX in promoting rheumatoid arthritis-like arthritis

1 reference

12 December 2020

10.1007/S00281-006-0012-9

Identifiers

DOI

1 reference

14 August 2017

1 reference